



04-25-02

1645

CASE 4-30476B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV041586452US

Express Mail Label Number

4/24/2002

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1645

RICHARD GARETH WARNER

APPLICATION NO: 09/692,249

FILED: OCTOBER 19, 2000

FOR: COMPOSITIONS AND THEIR USES

RECEIVED

APR 24 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231RESPONSE TO RESTRICTION REQUIREMENT

Sir:

The Examiner has issued a restriction requirement, dividing the claims of the case into an eight-way restriction, (22 is always in part):

I	1-10, 17-19, 22
II	11, 22
III	12, 22
IV	13-14, 22
V	15, 19, 22
VI	16, 19, 22
VII	20, 22
VIII	21-22

Election is made to the subject matter of Group I, claims 1-10, 17-19, and 22 in part.

The Examiner has further required election to a single therapeutic agent. The applicant hereby specifies that the protein-Gal α 1,3Gal conjugates, as in Claim 8, is elected.

Respectfully submitted,

Hesna J. Pfeiffer
Attorney for Applicant
Reg. No. 22,640

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6940
30476 response to restriction

Date: April 24, 2002

#4
A.Q.
5/2/02